Focus On Clinical Research Developments and Innovations
Executives from SynteractHCR, a full-service, international contract research organization (CRO), are continuing to speak at various industry conferences around the globe in October. The events include DIA/EFGCP/EMA Better Medicines for Children event in London, Oct. 10-11, the European Conference on Clinical Research in Prague, Oct. 17-18, and Outsourcing in Clinical Trials Southern California, which will be held in San Diego Oct. 26-27, 2016. Each event brings together thought leaders to network and stay abreast of trends and best practices in the clinical research industry.
Global Vice President Medical & Regulatory Affairs for SynteractHCR, Dr. Martine Dehlinger-Kremer, who is also the chair of the pediatric working group for EUCROF, will co-chair the opening session of the Better Medicines for Children conference on “Lessons Learned from 10 Years of Paediatric Regulation”. She will also participate on a panel titled “Initiation and Conduct of Pediatric Clinical Trials: Overcoming Challenges,” and will present at a break-out session titled, “The Work of the EFGVP Children Medicines Working Party and update on Ethical Considerations.”
SynteractHCR will then be heading to Prague for the European Conference on Clinical Research, Oct. 17-18, where Dr. Dehlinger-Kremer continues providing her expertise in the area of pediatric clinical trials by moderating a session titled, “Clinical Trials in the Paediatric Population.” She is also a presenter at the “Feasibility and Challenges with Paediatric Clinical Trials” session.
At Outsourcing in Clinical Trials Southern California in La Jolla, Senior Regulatory Affairs Manager Thomas Christensen will speak on “Preparing Proactively for FDA-mandated eCTD Submissions.” The presentation will provide critical insights into streamlining electronic common technical documents preparation as it becomes the standard submission format starting in 2017.
SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, immunotherapy, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision” philosophy, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data to help bring tomorrow’s treatments to patients.